U.S. Markets closed

Teva Pharmaceutical Is Facing These Challenges in 2019

Margaret Patrick
Teva Pharmaceutical Is Facing These Challenges in 2019

Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)Copaxone’s revenue erosionOn its first-quarter earnings conference call, Teva Pharmaceutical (TEVA) reaffirmed its 2019 global sales guidance of $1.30 billion for its